Analysts at Guggenheim downgraded their investment rating on Snapchat parent Snap Inc. (NYSE:SNAP) to "neutral" from "buy" on Tuesday. The research firm believes the company has well-defined broad ...

Guggenheim analyst Michael Morris downgraded Snap (SNAP) to Neutral from Buy with a price target of $11, down from $13. Snap plans to increase ...

Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.

Guggenheim Investments is the global ... and high-net-worth investors. Our 235+ investment professionals perform rigorous research to understand market trends and identify undervalued ...

The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...

“We are excited to have prominent institutional investors like AllianzGI and StepStone as LPs,” said Kevin Gundersen, Head of Guggenheim Corporate Funding, LLC, the private debt investment ...

Ms. Rubin will join Guggenheim with more than three decades ... where she was ranked as a top equity research analyst in the pharmaceutical industry. “Jami is an industry-leading intellect ...

About Guggenheim Investments Guggenheim Investments ... and high-net-worth investors. Our 235+ investment professionals perform rigorous research to understand market trends and identify undervalued ...